UCSF Helen Diller Comprehensive Cancer Center
University of California San Francisco
San Francisco, CA
Accepting patients
CARTITUDE-10
A Phase 2 Multicohort Trial to Further Characterize the Efficacy and Safety of Ciltacabtagene Autoleucel
- CAR T Cell
- BCMA
- Phase 2
Accepting patients
Talisman
A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity
- Bispecific Antibody
- GPRC5D
- Randomization
- Phase 2
Accepting patients
QUINTESSENTIAL
Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma
- CAR T Cell
- GPRC5D
- Phase 2
Not yet accepting
inMMyCAR
A Phase 1 Study to Evaluate the Safety of KLN-1010, a Novel, In Vivo Gene Therapy to Generate Anti-B Cell Maturation Antigen (Anti-BCMA) Chimeric Antigen Receptor-T Cells (CAR-T) in Patients With Relapsed and Refractory Multiple Myeloma
- CAR T Cell
- BCMA
- Phase 1
- Has results
Accepting patients
BMS-986453
A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
- CAR T Cell
- BCMA
- GPRC5D
- Phase 1
Accepting patients
Talquetamab with Iberdomide
A Phase Ib, Multi-center, Study of Talquetamab in Combination With Iberdomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
- Bispecific Antibody
- CD3
- GPRC5D
- Phase 1
Accepting patients
TRIlogy-3
A Phase 2, Open-label Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody
- Trispecific Antibody
- GPRC5D
- BCMA
- Phase 2
Accepting patients
JNJ-79635322
Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis
- Trispecific Antibody
- BCMA
- GPRC5D
- Phase 1
- Has results
Accepting patients
MMSET Inhibitor
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- H3K36me2
- Phase 1
- Has results
Accepting patients
DoMMino-1
A Phase II, Open-Label, Multicenter Study of Inobrodib in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- Bromodomain Inhibitor
- CBP (CREB-binding Protein) Inhibitor
- P300 Inhibitor
- Phase 2